CA2244693A1 - Methods for using the obese gene and its gene product to stimulate hematopoietic development - Google Patents

Methods for using the obese gene and its gene product to stimulate hematopoietic development Download PDF

Info

Publication number
CA2244693A1
CA2244693A1 CA002244693A CA2244693A CA2244693A1 CA 2244693 A1 CA2244693 A1 CA 2244693A1 CA 002244693 A CA002244693 A CA 002244693A CA 2244693 A CA2244693 A CA 2244693A CA 2244693 A1 CA2244693 A1 CA 2244693A1
Authority
CA
Canada
Prior art keywords
leptin
cells
hematopoietic
cell
cytokine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002244693A
Other languages
English (en)
French (fr)
Inventor
H. Ralph Snodgrass
Joseph Cioffi
Thomas J. Zupancic
Alan W. Shafer
Adel A. Mikhail
Bruce A. Barut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Indevus Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/618,957 external-priority patent/US6355237B1/en
Application filed by Individual filed Critical Individual
Publication of CA2244693A1 publication Critical patent/CA2244693A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0641—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/14—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/355—Leptin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Developmental Biology & Embryology (AREA)
CA002244693A 1996-01-23 1997-01-21 Methods for using the obese gene and its gene product to stimulate hematopoietic development Abandoned CA2244693A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US58991596A 1996-01-23 1996-01-23
US08/618,957 US6355237B1 (en) 1994-09-14 1996-03-20 Methods for using the obese gene and its gene product to stimulate hematopoietic development
US71329696A 1996-09-13 1996-09-13
US08/713,296 1996-09-13
US08/618,957 1996-09-13
US08/589,915 1996-09-13

Publications (1)

Publication Number Publication Date
CA2244693A1 true CA2244693A1 (en) 1997-07-31

Family

ID=27416556

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002244693A Abandoned CA2244693A1 (en) 1996-01-23 1997-01-21 Methods for using the obese gene and its gene product to stimulate hematopoietic development

Country Status (10)

Country Link
EP (2) EP1731164A1 (enExample)
JP (2) JP4018142B2 (enExample)
AT (1) ATE320479T1 (enExample)
AU (1) AU731685C (enExample)
CA (1) CA2244693A1 (enExample)
DE (1) DE69735477T2 (enExample)
DK (1) DK0892849T3 (enExample)
ES (1) ES2260784T3 (enExample)
PT (1) PT892849E (enExample)
WO (1) WO1997027286A1 (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6001968A (en) * 1994-08-17 1999-12-14 The Rockefeller University OB polypeptides, modified forms and compositions
ATE303437T1 (de) * 1996-01-04 2005-09-15 Amgen Inc Rezeptor des ob-proteins und verwandte zusammensetzungen und verfahren
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
IL120733A0 (en) * 1997-04-29 1997-08-14 Yeda Res & Dev Leptin as an inhibitor of cell proliferation
FR2767136B1 (fr) * 1997-08-06 2004-08-27 Genset Sa Recepteur complexe lsr, activite, clonage, et applications au diagnostic, a la prevention et/ou au traitement de l'obesite et des risques ou complications associes
FR2767135B1 (fr) 1997-08-06 2002-07-12 Genset Sa Recepteur complexe lsr, activite, clonage, et application au diagnostic, a la prevention et/ou au traitement de d'obesite et des risques ou complications associes
AU4672199A (en) * 1998-05-20 1999-12-06 Yale University Modulation of angiogenesis and wound healing
US7208572B2 (en) 1998-08-21 2007-04-24 Albany Medical College Leptin-related peptides
US6777388B1 (en) 1998-08-21 2004-08-17 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
IL141683A0 (en) * 1998-08-31 2002-03-10 Univ New York Stem cells bearing an fgf receptor on the cell surface
EP1127120B1 (en) 1998-11-04 2008-05-28 Serono Genetics Institute S.A. Genomic and complete cdna sequences of human adipocyte-specific apm1 and biallelic markers thereof
CA2359757A1 (en) 1999-02-10 2000-08-17 Genset S.A. Polymorphic markers of the lsr gene
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
IL132312A0 (en) * 1999-09-05 2001-03-19 Yeda Res & Dev Use of leptin in inhibition of endothelial cell proliferation
US6566332B2 (en) 2000-01-14 2003-05-20 Genset S.A. OBG3 globular head and uses thereof for decreasing body mass
US6989367B2 (en) 2000-01-14 2006-01-24 Genset S.A. OBG3 globular head and uses thereof
US7338787B2 (en) 2000-01-14 2008-03-04 Serono Genetics Institute S.A. Nucleic acids encoding OBG3 globular head and uses thereof
US20020058617A1 (en) 2000-01-14 2002-05-16 Joachim Fruebis OBG3 globular head and uses thereof for decreasing body mass
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
EP1718665B1 (en) 2004-02-11 2013-04-10 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2006213607A1 (en) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Llc GIP analog and hybrid polypeptides with selectable properties
EP1922336B1 (en) 2005-08-11 2012-11-21 Amylin Pharmaceuticals, LLC Hybrid polypeptides with selectable properties
EP2330125A3 (en) 2005-08-11 2012-12-12 Amylin Pharmaceuticals, Inc. Hybrid polypeptides with selectable properties
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
TWI752920B (zh) 2015-10-12 2022-01-21 美商再生元醫藥公司 活化瘦素受體的抗原結合蛋白
FI3538554T3 (fi) 2016-11-08 2025-09-24 Regeneron Pharma Antigeeniä sitovia proteiineja, jotka antagonisoivat leptiinireseptoria
AU2018390811A1 (en) 2017-12-18 2020-07-02 Regeneron Pharmaceuticals, Inc. Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof
CA3094400A1 (en) 2018-04-06 2019-10-10 Regeneron Pharmaceuticals, Inc. A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia
WO2020023621A1 (en) * 2018-07-24 2020-01-30 Puneeth Iyengar Improved weight loss therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643748A (en) * 1994-09-14 1997-07-01 Progenitor, Inc. HU-B1.219, a novel human hematopoietin receptor

Also Published As

Publication number Publication date
EP0892849A1 (en) 1999-01-27
ES2260784T3 (es) 2006-11-01
WO1997027286A1 (en) 1997-07-31
AU731685B2 (en) 2001-04-05
DK0892849T3 (da) 2006-07-24
EP0892849B1 (en) 2006-03-15
EP0892849A4 (en) 2004-08-25
PT892849E (pt) 2006-08-31
JP4018142B2 (ja) 2007-12-05
EP1731164A1 (en) 2006-12-13
JP2007163502A (ja) 2007-06-28
AU731685C (en) 2002-08-22
DE69735477D1 (de) 2006-05-11
JP2001510982A (ja) 2001-08-07
DE69735477T2 (de) 2006-11-30
ATE320479T1 (de) 2006-04-15
AU1831197A (en) 1997-08-20

Similar Documents

Publication Publication Date Title
AU731685B2 (en) Methods for using the obese gene and its gene product to stimulate hematopoietic development
WO1997027286A9 (en) Methods for using the obese gene and its gene product to stimulate hematopoietic development
AU689948B2 (en) Hu-b1.219, a novel human hematopoietin receptor
KR100319359B1 (ko) flt3수용체에대한리간드
Paul et al. Molecular cloning of a cDNA encoding interleukin 11, a stromal cell-derived lymphopoietic and hematopoietic cytokine.
Porteu et al. Functional regions of the mouse thrombopoietin receptor cytoplasmic domain: evidence for a critical region which is involved in differentiation and can be complemented by erythropoietin
Jenkins et al. Activating point mutations in the common beta subunit of the human GM‐CSF, IL‐3 and IL‐5 receptors suggest the involvement of beta subunit dimerization and cell type‐specific molecules in signalling.
WO1997021802A1 (en) Novel embryonic cell populations and methods to isolate such populations
US5763211A (en) Isolated nucleic acid encoding Hu-B1.219, a novel human hematopoietin
US6613565B1 (en) Use of delta-like protein to inhibit the differentiation of stem cells
US20040072259A1 (en) Methods and products for manipulating hematopoietic stem cells
US6838079B2 (en) Methods for using the obese product to stimulate hematopoietic development
US20050238628A1 (en) Methods for treating cancer
Valtieri et al. Efficient transfer of selectable and membrane reporter genes in hematopoietic progenitor and stem cells purified from human peripheral blood
IZUMI-HISHA et al. Monoclonal antibodies against a preadipose cell line (MC3T3-G2/PA6) which can support hemopoiesis
US20120201792A1 (en) Methods and products for manipulating hematopoietic stem cells
Testa et al. Differential Expression Of IL-3 and GM-CSF Receptor Common Signal Transducing Subunit (βC) During Normal Hematopoietic Differentiation
SIGNAL TRANSDUCING SUBUNIT (ẞC) DURING
Krosl The role of erythropoietin and erythropoietin receptor in regulation of hemopoiesis
Cáceres-Cortés The role of steel factor (SF) in the biology of human acute myeloblastic leukemia and normal CD34+ hematopoietic cells
Chen JAK2 kinase as an effector of mitogenesis signaling via the EPO receptor andc-KIT
Lin Studies of the role of transcription factor GATA-1 and the erythropoietin receptor in hematopoiesis
Murthy Studies into the mechanism of action of interleukin 3: purification of interleukin 3 and characterization of its cell surface receptor

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued
FZDE Discontinued

Effective date: 20090928